Cytox Announces Participation in INSIGHT Alzheimer’s Study

Participation will aid comparison of SNP genotyping with biomarker status

OXFORD, England–(BUSINESS WIRE)–Cytox Ltd, an innovative developer of assays for risk assessment and
prediction of dementia, has confirmed its participation in the
pioneering French INSIGHT study of Alzheimer’s disease (AD). The Cytox
proposal, ‘Single Nucleotide Polymorphism (SNP) Profiling as an Approach
to Risk Stratification for Future Cognitive Decline in Elderly
Subjective Memory Complainers’, has been reviewed and approved by the
INSIGHT Scientific Committee.

INSIGHT is a study of Alzheimer’s disease and one of the first in the
world to monitor healthy subjects at risk. Led by Professor Harald
Hampel, AXA-UPMC Chair at Université Pierre et Marie Curie, Paris,
France and Professor Bruno Dubois, Director of IM2A (Institute of Memory
and Alzheimer’s Disease, located at La Pitié Salpêtrière University
Hospital in Paris), and based at the ICM (Brain and Spine Institute,
Paris), the study is a collaboration with Pfizer and Avid. The project
involves monitoring 350 healthy volunteer subjects aged 70-85 years,
with normal memory function that are stratified in a group that is
amyloid-positive and a control group that is negative as defined by PET.
Its objective is not to detect or treat disease, but to observe changes
in these healthy subjects eventually progressing to first clinical
symptoms related to Alzheimer’s disease. The seven-year study is being
conducted at the IM2A and ICM. INSIGHT is an ancillary study of the
French MEMENTO national cohort.

This affords Cytox an excellent opportunity to generate initial
cross-sectional data according to Dr. Richard Pither, CEO of Cytox, “All
of these subjects in Paris have been assessed in an internationally
unique mono-centre setting using an extensive range of standardized
methods, clinical and biomarkers, allowing us to compare our SNP
genotyping results with biomarker status, including CSF and PET-amyloid
imaging, and then, in time, longitudinal data as these subjects are
followed up in coming years. These samples are likely to represent a
good proportion of our first genotyping analysis using the
Cytox-Affymetrix genoTOR MKI Research array.”

Further info:

Cytox Limited
www.cytoxgroup.com/information-for-editors
www.cytoxgroup.com

INSIGHT www.icm-institute.org/en/alzheimer-en

Contacts

Cytox Ltd
Richard Pither, CEO, +44 (0)1865 338018
richard.pither@cytoxgroup.com